Transforming concepts into safe, scalable drug products.
From simple tablets to complex injectable formulations — high-quality drug products engineered for performance, safety, and regulatory compliance.
An integrated formulation platform.
Airis Pharma specializes in transforming innovative concepts into safe, effective, and scalable pharmaceutical products. From simple tablets to complex injectable formulations, we focus on developing high-quality drug products that meet the diverse needs of the pharmaceutical industry.
Our formulation development services cover a wide array of dosage forms, advanced drug delivery technologies, and robust equipment capabilities — all built around performance, safety, and regulatory compliance.
Three platform families. Three execution disciplines.
01 · Dosage-Form Platforms
- Immediate Release (IR) tablets & capsules
- Delayed Release (DR) — enteric-coated
- Taste-Masked ODT (orally disintegrating)
- Modified Release — Matrix & Diffusion
- Multi-Particulate (IR / SR / DR)
- Bi-Layer & Tri-Layer Tablets
- Tablet-in-Capsule architectures
- Pellets & Wurster-coated systems
- Oral Liquids & Suspensions
- PFOS / Powder for Oral Suspension & Dry Syrups
- Sterile Injectables (incl. PFS format)
- Gels, Creams, Ointments & Topical Semi-Solids
- Closed-transfer dispensing → manufacturing
- OEB 4-5 / OEL <1µg/m³ contained operations
- Dedicated high-potent cream platform
- Four-stage containment workflow
Formulation & delivery technologies.
02 · Technology PlatformsCutting-edge technologies applied selectively under Quality-by-Design (QbD) principles — translating R&D complexity into predictable, regulator-ready outcomes. Sound expertise developing First-to-File, Paragraph IV, NCE, and non-infringing formulations across USFDA, MHRA, Health Canada, and emerging markets.
5,000 sq. ft. of real equipment.
Two dedicated wings — Formulation Research (476 sq. ft.) and Analytical Research (956 sq. ft.) — supported by 120 KVA backup power, dedicated UPS systems, and controlled-RH environments. Every photo on this page is the actual Airis R&D floor.
Equipment & process capabilities.
03 · R&D Manufacturing FloorAn R&D laboratory of 5,000 sq. ft. across two dedicated wings — Formulation Research and Analytical Research — fully equipped for oral solids, liquids, semi-solids, and simple injectables. Utilities: 120 KVA electricity with 2× 120 KVA backup generators; 2× 60 kW UPS; 5 HP & 15 HP compressed air.